Zacks Investment Research upgraded Accelerate Diagnostics Inc (NASDAQ:AXDX) to Hold in a report released today.
- Updated: September 19, 2016
Showing a price of $28.00, Accelerate Diagnostics Inc (NASDAQ:AXDX) traded 4.01% higher on the day. With the last stock close up 71.09% relative to the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. The company has logged a 50-day average of $22.87 and two hundred day moving average of $16.54. Trading volume was was up over the average, with 514,661 shares of AXDX changing hands over the typical 342,369 shares.
Zacks Investment Research has upgraded Accelerate Diagnostics Inc(NASDAQ:AXDX) to Hold in a statement released 9/19/2016.
See Graph Below:
A total of 2 brokers have released a ratings update on the company. Two firms rate the company a strong buy, one analyst rate the company a buy, 0 analysts rate the stock a hold, 0 rate the stock to underperform, and lastly 0 brokeragesrate the company as sell with a 12-month target price of $25.50
With a market capitalization of $0.0, Accelerate Diagnostics Inc has a one-year low of $10.29 and a one-year high of $28.50 with a price-earnings ratio of 0.
Brief Synopsis About Accelerate Diagnostics Inc (NASDAQ:AXDX)
Accelerate Diagnostics, Inc. is an in vitro diagnostics company engaged in providing solutions that improve patient outcomes and lower healthcare costs through the diagnosis of serious infections. The Company’s technology platform is built to address these challenges by delivering testing of infectious pathogens in various patient sample types. The Company is focused on the development of a rapid diagnostic platform, the Accelerate ID/AST System (ID/AST System or Accelerate ID/AST System), intended for the diagnosis of infectious pathogens. The ID/AST System utilizes genotypic technology to identify (ID) infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), and which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. The ID/AST System features walk-away automation and consists of a fixed instrument and single-use test kit.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.